The global AI in drug discovery market is projected to grow from USD 1.76 billion in 2024 to USD 13.44 billion by 2035, representing a robust CAGR of 20% during the forecast period. The increasing adoption of artificial intelligence and machine learning algorithms across pharmaceutical R&D is significantly reshaping traditional drug development approaches, leading to strong growth across the market.
Roots Analysis’s latest study, "AI Drug Discovery Market," provides a comprehensive overview of how computational tools are transforming the pharmaceutical landscape. It analyzes historical trends and offers projections, illustrating how deep learning, predictive modeling, and molecular simulation are accelerating new drug identification and design processes within the AI in drug discovery market.
The study highlights key growth drivers, including the need to reduce time-to-market, improve early-stage success rates, and lower R&D costs. It also explores emerging opportunities, such as AI-driven repurposing of existing molecules and integration with high-throughput screening platforms.
Competitive Landscape
Leading players driving innovation in the AI in drug discovery market include Aiforia Technologies, Atomwise, BioSyntagma, Chemalive, Collaborations Pharmaceuticals, Cyclica, DeepMatter, Recursion, InveniAI, MAbSilico, Optibrium, Recursion Pharmaceuticals, Sensyne Health, and Valo Health.
These companies are enhancing traditional workflows by applying AI models to various drug discovery stages, including hit generation, target validation, and lead optimization. Increasing partnerships between AI firms and pharmaceutical giants are reshaping how new therapies are discovered and developed.
https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html
Market Segmentation
The AI drug discovery market is segmented across multiple parameters that shape its dynamic evolution:
- By Drug Discovery Step:
AI applications span target identification/validation, hit generation/lead identification, and lead optimization, dramatically improving efficiency at every stage. - By Therapeutic Area:
AI platforms are widely applied in oncological disorders, CNS disorders, infectious diseases, respiratory diseases, cardiovascular disorders, endocrine diseases, gastrointestinal disorders, musculoskeletal disorders, immunological disorders, dermatological disorders, and other therapeutic fields. - By Geography:
The AI in drug discovery market is gaining traction globally, particularly across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa, reflecting both mature and emerging healthcare technology ecosystems.
Research Methodology
This study is based on a combination of primary interviews with AI developers, pharmaceutical scientists, and biotech executives, alongside secondary research from academic journals, patent databases, regulatory filings, and industry reports. Advanced market modeling techniques and data triangulation were employed to generate forward-looking insights into the market, ensuring accurate and actionable intelligence.
